Alliance Pharma PLC PDMR shareholding (8887W)
February 14 2017 - 12:31PM
UK Regulatory
TIDMAPH
RNS Number : 8887W
Alliance Pharma PLC
14 February 2017
For immediate release 14 February 2017
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
PDMR shareholding
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical
company, announces that Peter Butterfield, a director of the
Company and its Deputy CEO has today exercised an option granted
under an employee share scheme over 90,222 ordinary shares of 1p
each in the Company at 33.25p per share, and immediately sold
61,846 of these shares on the London Stock Exchange at a price of
48.75p per share to fund the subscription price and associated
dealing costs.
Following these linked transactions, Mr Butterfield has a
beneficial interest in 28,376 shares in the Company and holds
options over a further 4,349,803 shares granted under the Company's
employee share schemes.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Andrew Franklin, Chief Financial
Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
+ 44 (0) 20 7466
Buchanan 5000
Mark Court / Sophie Cowles
/ Jane Glover
+ 44 (0) 20 7260
Numis Securities Limited 1000
Nominated Adviser: Michael
Meade / Freddie Barnfield
Corporate Broking: James
Black / Toby Adcock
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international speciality
pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has sales in more than 100 countries worldwide via direct
sales, joint ventures and a network of distributors. Alliance has a
strong track record of acquiring the rights to established niche
products and it currently owns or licenses the rights to
approximately 90 pharmaceutical and consumer healthcare products.
The Company continues to explore opportunities to expand its
product portfolio.
Alliance joined the AIM market of the London Stock Exchange in
December 2003 and trades under the symbol APH.
ANNEX
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ---------------------------------------------------------------
a) Name Peter Butterfield
--- ------------------------- ------------------------------------
2 Reason for the notification
--- ---------------------------------------------------------------
a) Position/status Deputy Chief Executive Officer
--- ------------------------- ------------------------------------
b) Initial notification Initial
/Amendment
--- ------------------------- ------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ---------------------------------------------------------------
a) Name Alliance Pharma plc
--- ------------------------- ------------------------------------
b) LEI n/a
--- ------------------------- ------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ---------------------------------------------------------------
a) Description of 1p ordinary shares
the financial
instrument, type ISIN: GB0031030819
of instrument
Identification
code
--- ------------------------- ------------------------------------
b) Nature of the 1. Exercise of options
transaction 2. Sale
--- ------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------------- ----------------
1) 33.25p 1) 90,222
2) 48.75p 2) 61,846
---------------- ----------------
--- ------------------------- ------------------------------------
d) Aggregated information Exercise of 90,222 options
at an exercise price of 33.25p
per share
- Aggregated volume
Sale of 61,846 shares at
a price of 48.75p per share
- Price
--- ------------------------- ------------------------------------
e) Date of the transaction 14 February 2017
--- ------------------------- ------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--- ------------------------- ------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBRGDDRDBBGRS
(END) Dow Jones Newswires
February 14, 2017 12:31 ET (17:31 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024